Expanded Access Remdesivir (RDV; GS-5734™)

Inclusion Criteria: * DoD-affiliated personnel as defined in DoDI 6200.02, which includes emergency-essential civilian employees and/or contractor personnel accompanying the Armed Forces who are subject to the same health risk as military personnel * Have a laboratory-confirmed COVID-19 diagnosis with moderate to severe disease presentation as determined by the principal investigator * Patient or legally authorized representative (LAR) provides written informed consent, except as noted in 21 CFR 50.23 * Understands and agrees to comply with planned study procedures * Available for clinical follow-up for duration of the treatment and follow-up period * Woman of childbearing potential must * Have a negative pregnancy test within 24 hours before starting treatment * Agree not to become pregnant during treatment and for 1 months after receiving remdesivir (Treatment will be a maximum of 10 doses given over a 10-day interval) * Use at least 2 reliable forms of effective contraception, including 1 barrier method, during treatment and for 1 month after the treatment period Exclusion Criteria: * ALT/AST ≥ 5 times the upper limit of normal * Stage 4 severe kidney disease or requiring dialysis (i.e. eGFR \<30) * Anticipated transfer to another hospital that is not a study site within 72 hours * Allergy to any components of the study medication \[GS-5734, sulfobutylether β-cyclodextrin sodium (SBECD) and hydrochloric acid and/or sodium hydroxide\] * Concomitant antiviral therapy (lopinavir/ritonavir \[Kaletra\]) * Pregnant or nursing